A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2011
05/19/2011	US20110117188 Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof
05/19/2011	US20110117185 Methods for treating or preventing heart damage with integrin-linked kinase (ilk) compositions
05/19/2011	US20110117184 Compositions for mucosal delivery of agents
05/19/2011	US20110117181 Treating hepatitis c virus infection with over-expression of microrna-196
05/19/2011	US20110117180 Vegetarian microcapsules
05/19/2011	US20110117173 Powdered chewing gum compositions, the use thereof and a method of preparing such compositions
05/19/2011	US20110117170 Controlled Release of Growth Factors and Signaling Molecules for Promoting Angiogenesis
05/19/2011	US20110117168 Methods and compositions for soft tissue repair
05/19/2011	US20110117167 Methods and compositions for soft tissue repair
05/19/2011	US20110117166 Implantable bone graft materials
05/19/2011	US20110117163 Bioactive coating for an implantable device or bioprosthesis
05/19/2011	US20110117154 Use of rifalazil to treat colonic disorders
05/19/2011	US20110117139 Fully synthetic albumin analog
05/19/2011	US20110117130 Method of diagnosing and treating Ehrlichia
05/19/2011	US20110117118 Molecules, compositions, methods and kits for applications associated with flaviviruses
05/19/2011	US20110117116 Nucleic acids encoding a house dust mite allergen, der p iii, and uses therefor
05/19/2011	US20110117115 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
05/19/2011	US20110117112 Sodium channel protein type iii alpha-subunit splice variant
05/19/2011	US20110117111 Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
05/19/2011	US20110117109 Cytomegalovirus disintegrin-like peptides
05/19/2011	US20110117107 Compositions and methods for diagnosis, prognosis and management of malaria
05/19/2011	US20110117106 Uses of calpain inhibitors to inhibit inflammation
05/19/2011	US20110117101 Cc chemokine receptor 5 dna, new animal models and therapeutic agents for hiv infection
05/19/2011	US20110117094 Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury
05/19/2011	US20110117082 Soluble Tumor Necrosis Factor Receptor Mutant
05/19/2011	US20110117075 Thrombin derived peptides for smooth muscle relaxation
05/19/2011	US20110117074 Methods of treating hiv and influenza infections using aspergillus oryzae protease
05/19/2011	US20110117073 Protein Kinase Conjugates and Inhibitors
05/19/2011	US20110117071 Antimicrobial Composition
05/19/2011	US20110117067 Glucanases, Nucleic Acids Encoding Them and Methods for Making and Using Them
05/19/2011	US20110117057 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
05/19/2011	US20110117056 Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
05/19/2011	US20110117055 Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
05/19/2011	US20110117054 Use of ribavirin in blood coagulation disorder
05/19/2011	US20110117053 Method of modulating fibroblast accumulation or collagen deposition
05/19/2011	US20110117052 Methods of treatment using il-31ra
05/19/2011	US20110117051 Method for inducing and accelerating cells
05/19/2011	US20110117050 Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen
05/19/2011	US20110117049 Methods and Compositions for Modulating Adipocyte Function
05/19/2011	US20110117027 Injectable void filler for soft tissue augmentation
05/19/2011	US20110117024 Nanocarrier and nanogel compositions
05/19/2011	US20110117022 Method of using and establishing an absorption rate level and a neuron firing level
05/19/2011	US20110117018 Compositions and methods for treating bone
05/19/2011	US20110117017 Peptides with properties of an allosteric antagonist selective for the alpha 1a adrenergic receptor and uses thereof
05/19/2011	US20110117011 Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
05/19/2011	US20110117009 Drug conjugates with polyglycerols
05/19/2011	US20110114524 Storage-stable, functionally intact fibrinogen
05/19/2011	CA2817495A1 Compositions, methods and uses for stimulating immune responses
05/19/2011	CA2781008A1 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
05/19/2011	CA2780835A1 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections
05/19/2011	CA2780763A1 Factor viii b cell epitope variants having reduced immunogenicity
05/19/2011	CA2780761A1 Factor viii t cell epitope variants having reduced immunogenicity
05/19/2011	CA2780542A1 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
05/19/2011	CA2780460A1 Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
05/19/2011	CA2780457A1 Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
05/19/2011	CA2780043A1 Pharmaceutical composition comprising a glp-1 agonist and methionine
05/19/2011	CA2779417A1 Therapeutic agent for gastrointestinal disease
05/19/2011	CA2779290A1 Ligand-targeted multi-stereoisomer peptide polymer conjugates and uses thereof
05/19/2011	CA2778839A1 Glycosyl transferase from chinese hamster and related methods
05/18/2011	EP2322933A1 Diagnosis of carcinomas
05/18/2011	EP2322648A1 RNA aptamers and methods for identifying the same
05/18/2011	EP2322644A1 Methods for producing modified glycoproteins
05/18/2011	EP2322631A1 In vivo incorporation of unnatural amino acids
05/18/2011	EP2322628A2 Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
05/18/2011	EP2322627A2 Mutations in the BCR-abl tyrosine kinase associated with resistance to STI-571
05/18/2011	EP2322625A1 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
05/18/2011	EP2322620A2 Analogs of human pancreatic polypeptide and their effects on feeding behaviour
05/18/2011	EP2322618A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
05/18/2011	EP2322558A1 Antibodies directed against glycoprotein VI and uses thereof
05/18/2011	EP2322553A2 Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
05/18/2011	EP2322546A1 Acylated GLP-1 compounds
05/18/2011	EP2322545A1 Analogues of GLP-1
05/18/2011	EP2322541A1 Gq protein competitive inhibitory polypeptides, preparation methods and uses thereof
05/18/2011	EP2322538A1 Compounds for the diagnosis of diseases associated with VCAM expression
05/18/2011	EP2322536A2 Aminothiazole derivatives and their uses as antibacterial agents
05/18/2011	EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
05/18/2011	EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof
05/18/2011	EP2322226A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation
05/18/2011	EP2322224A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof
05/18/2011	EP2322216A1 A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
05/18/2011	EP2322209A2 Tumor specific oligosaccharide epitopes and use thereof
05/18/2011	EP2322208A2 Bowman-Birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease
05/18/2011	EP2322207A2 Oxygen-transferring blood substitute and a pharmaceutical composition (variants)
05/18/2011	EP2322206A2 Mutated netrin 1, fragments thereof and uses thereof as drugs
05/18/2011	EP2322205A1 Polymer-conjugated glycosylated neublastin
05/18/2011	EP2322204A1 Pharmaceutical compositions comprising an LRP1 receptor agonist for the treatment of cancer and HIV
05/18/2011	EP2322203A2 Compositions and methods for the treatment of immune related diseases
05/18/2011	EP2322202A2 Compositions and methods for the treatment of immune diseases
05/18/2011	EP2322201A2 Compositions and methods for the treatment of immune related diseases
05/18/2011	EP2322200A2 Compositions and methods for the treatment of immune related diseases
05/18/2011	EP2322199A1 Growth differentiation factor receptors, and methods of using same
05/18/2011	EP2322198A2 Pharmaceutical compositions including low dosages of desmopressin
05/18/2011	EP2322197A2 Pharmaceutical compositions including low dosages of desmopressin
05/18/2011	EP2322196A2 Pharmaceutical compositions including low dosages of desmopressin
05/18/2011	EP2322195A2 Pharmaceutical compositions including low dosages of desmopressin
05/18/2011	EP2322194A2 Pharmaceutical compositions including low dosages of desmopressin
05/18/2011	EP2322191A2 Senescence control composition containing extracellular matrix components, and senescence control method for senescent cells using same
05/18/2011	EP2322189A2 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
05/18/2011	EP2322185A2 Polynucleotide therapy
05/18/2011	EP2322177A1 Use of a preparation based on nifedipine for treating vaginismus

1 ... 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 ... 3163